Coherus Biosciences (CHRS) PT Raised to $25 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Coherus Biosciences (CHRS) PT Raised to $25 at Citi Following 4Q and FDA Meeting
March 9, 2018 7:20 AM ESTCiti raised its price target on Coherus Biosciences (NASDAQ: CHRS) to $25.00 (from $23.00) while maintaining a Buy rating following the company's 4Q earnings report. Management highlighted the company's FDA meeting and the discussion of immunogenicity assay for Neulasta biosimilar. They noted that the... More
Coherus Biosciences (CHRS) PT Lowered to $15 at Maxim Group
March 9, 2018 6:59 AM ESTMaxim Group lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $15.00 (from $20.00) while maintaining a Buy rating.
... More